A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

Figure 5

Verification of the signature’s distinguishing ability in different clinical subgroups of GSE14520. (a–i) K–M curves for differences in OS among different clinical subgroups of patients in GSE14520 treated with TACE ( and >50; tumor ; ; Barcelona Clinic Liver Cancer (BCLC) staging system stage A; cirrhosis; TNM stages I, II, and III).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)